Pfizer is attempting to receive approval to reimburse its JAK inhibitor ‘Cibinqo’ in atopic dermatitis (AD) for both adults and adolescents in Korea.

According to industry sources, Pfizer Korea resubmitted an application for the reimbursement approval of its new janus kinases (JAK) inhibitor ‘Cibinqo (abrocitinib)’ at the end of last year.

After the drug passed the review of the National Health Insurance Review and Assessment Service’s Drug Reimbursement Standard Subcommittee in August last year, no news had been heard of its deliberation by the Drug Reimbursement Evaluation Committee. This time, the company is attempting to receive reimbursement approval for the drug in adolescent